Fujian Cosunter Pharmaceutical Co Ltd (300436) - Total Assets
Based on the latest financial reports, Fujian Cosunter Pharmaceutical Co Ltd (300436) holds total assets worth CN¥1.41 Billion CNY (≈ $206.91 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Fujian Cosunter Pharmaceutical Co Ltd (300436) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Fujian Cosunter Pharmaceutical Co Ltd - Total Assets Trend (2011–2025)
This chart illustrates how Fujian Cosunter Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See Fujian Cosunter Pharmaceutical Co Ltd shareholders equity for net asset value and shareholders' equity analysis.
Fujian Cosunter Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Fujian Cosunter Pharmaceutical Co Ltd's total assets of CN¥1.41 Billion consist of 36.5% current assets and 63.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 15.3% |
| Accounts Receivable | CN¥76.25 Million | 5.4% |
| Inventory | CN¥124.85 Million | 8.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥188.97 Million | 13.5% |
| Goodwill | CN¥58.97 Million | 4.2% |
Asset Composition Trend (2011–2025)
This chart illustrates how Fujian Cosunter Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Fujian Cosunter Pharmaceutical Co Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fujian Cosunter Pharmaceutical Co Ltd's current assets represent 36.5% of total assets in 2025, a decrease from 47.1% in 2011.
- Cash Position: Cash and equivalents constituted 15.3% of total assets in 2025, down from 35.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 9.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 13.5% of total assets.
Fujian Cosunter Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Fujian Cosunter Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.25 Billion |
|
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089
|
China | CN¥4.69 Billion |
|
Akums Drugs and Pharmaceutical
NSE:AKUMS
|
India | Rs51.59 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Tibet Weixinkang Medicine Co Ltd
SHG:603676
|
China | CN¥1.95 Billion |
Fujian Cosunter Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.02 | 0.69 | 2.31 |
| Quick Ratio | 0.77 | 0.47 | 2.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥8.63 Million | CN¥-170.03 Million | CN¥381.95 Million |
Fujian Cosunter Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Fujian Cosunter Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 54.30 |
| Latest Market Cap to Assets Ratio | 1.52 |
| Asset Growth Rate (YoY) | -2.7% |
| Total Assets | CN¥1.40 Billion |
| Market Capitalization | $2.13 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Fujian Cosunter Pharmaceutical Co Ltd's assets above their book value (1.52x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Fujian Cosunter Pharmaceutical Co Ltd's assets decreased by 2.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Fujian Cosunter Pharmaceutical Co Ltd (2011–2025)
The table below shows the annual total assets of Fujian Cosunter Pharmaceutical Co Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.40 Billion ≈ $204.93 Million |
-2.66% |
| 2024-12-31 | CN¥1.44 Billion ≈ $210.54 Million |
-10.88% |
| 2023-12-31 | CN¥1.61 Billion ≈ $236.25 Million |
+8.00% |
| 2022-12-31 | CN¥1.49 Billion ≈ $218.74 Million |
+3.32% |
| 2021-12-31 | CN¥1.45 Billion ≈ $211.71 Million |
+43.80% |
| 2020-12-31 | CN¥1.01 Billion ≈ $147.22 Million |
+12.25% |
| 2019-12-31 | CN¥896.25 Million ≈ $131.15 Million |
+4.86% |
| 2018-12-31 | CN¥854.68 Million ≈ $125.07 Million |
+16.05% |
| 2017-12-31 | CN¥736.47 Million ≈ $107.77 Million |
+5.11% |
| 2016-12-31 | CN¥700.67 Million ≈ $102.53 Million |
+16.64% |
| 2015-12-31 | CN¥600.70 Million ≈ $87.90 Million |
+168.03% |
| 2014-12-31 | CN¥224.11 Million ≈ $32.79 Million |
+13.46% |
| 2013-12-31 | CN¥197.53 Million ≈ $28.90 Million |
+32.21% |
| 2012-12-31 | CN¥149.41 Million ≈ $21.86 Million |
+36.71% |
| 2011-12-31 | CN¥109.29 Million ≈ $15.99 Million |
-- |
About Fujian Cosunter Pharmaceutical Co Ltd
Fujian Cosunter Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It offers drugs for anti-HBV, liver diseases, hepatobiliary disease drugs, metabolism and digestive system, respiratory, cardiovascular, men's health, and other fields. Fujian Cosunter Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Fuzh… Read more